Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 210.4% in July

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totaling 9,938 shares, an increase of 210.4% from the June 30th total of 3,202 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 6,876 shares, the short-interest ratio is currently 1.4 days.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Pharming Group in a report on Friday, April 10th. They issued a “buy” rating and a $37.00 target price for the company. Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Wall Street Zen cut Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Weiss Ratings downgraded Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pharming Group presently has an average rating of “Hold” and a consensus target price of $38.33.

Institutional Trading of Pharming Group

Several large investors have recently modified their holdings of PHAR. EverSource Wealth Advisors LLC purchased a new stake in Pharming Group in the 2nd quarter valued at approximately $32,000. SmartHarvest Portfolios LLC purchased a new position in Pharming Group during the fourth quarter worth $224,000. Millennium Management LLC purchased a new position in Pharming Group during the fourth quarter worth $360,000. Finally, NewEdge Advisors LLC increased its position in Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after buying an additional 28,615 shares in the last quarter. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Trading Down 1.2%

NASDAQ:PHAR opened at $12.86 on Wednesday. Pharming Group has a 52-week low of $9.54 and a 52-week high of $21.34. The company has a quick ratio of 2.06, a current ratio of 2.63 and a debt-to-equity ratio of 0.35. The stock has a fifty day simple moving average of $13.13 and a 200-day simple moving average of $15.33. The company has a market capitalization of $910.23 million, a PE ratio of 80.38 and a beta of -0.04.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. The business had revenue of $72.45 million during the quarter, compared to analyst estimates of $92.06 million. On average, equities research analysts expect that Pharming Group will post 0.6 earnings per share for the current fiscal year.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.